Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

European Journal of Immunology

Volumn 41, Issue 10, 2011, Pages 2977-2986

  Mkrtichyan, Mikayel ^a   Najjar, Yana G ^a   Raulfs, Estella C ^a   Abdalla, Maher Y ^a   Samara, Raed ^a   Rotem Yehudar, Rinat ^b   Cook, Larry ^c   Khleif, Samir N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CureTech Ltd   (Israel)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cancer immunotherapy; Programmed death 1 receptor; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CT 011; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FEMALE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, REGULATORY;

EID: 80053161751     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141639     Document Type: Article

References (46)

1. Hachisuka, T., Narikiyo, M., Yamada, Y., Ishikawa, H., Ueno, M., Uchida, H., Yoriki, R. et al., High lymphatic vessel density correlates with overexpression of VEGF-C in gastric cancer. Oncol. Rep. 2005. 13: 733-737.
2. Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T. and Gajewski, T. F., PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+T cells. Cancer Res. 2004. 64: 1140-1145.
3. Keir, M. E., Latchman, Y. E., Freeman, G. J. and Sharpe, A. H., Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J. Immunol. 2005. 175: 7372-7379.
4. Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H. and Nishimura, M., B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 2004. 10: 5094-5100.
5. Okazaki, T. and Honjo, T., The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006. 27: 195-201.
6. Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y. et al., PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001. 2: 261-268.
7. Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T. et al., Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 2005. 11: 2947-2953.
8. Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S. et al., Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 2007. 13: 2151-2157.
9. Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G. et al., Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. USA 2004. 101: 17174-17179.
10. Ghebeh, H., Mohammed, S., Al-Omair, A., Qattan, A., Lehe, C., Al-Qudaihi, G., Elkum, N. et al., The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006. 8: 190-198.
11. Thompson, R. H. and Kwon, E. D., Significance of B7-H1 overexpression in kidney cancer. Clin. Genitourin Cancer 2006. 5: 206-211.
12. Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T. et al., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 2007. 104: 3360-3365.
13. Tsushima, F., Tanaka, K., Otsuki, N., Youngnak, P., Iwai, H., Omura, K. and Azuma, M., Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 2006. 42: 268-274.
14. Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J. et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000. 192: 1027-1034.
15. Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S. et al., CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 2005. 25: 9543-9553.
16. Seo, S. K., Seo, H. M., Jeong, H. Y., Choi, I. W., Park, Y. M., Yagita, H., Chen, L. et al., Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol. Lett. 2006. 102: 222-228.
17. Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H. and Fujii, H., Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 2003. 9: 4404-4408.
18. Gallimore, A. and Godkin, A., Regulatory T cells and tumour immunity - observations in mice and men. Immunology 2008. 123: 157-163.
19. Ikemoto, T., Yamaguchi, T., Morine, Y., Imura, S., Soejima, Y., Fujii, M., Maekawa, Y. et al., Clinical roles of increased populations of Foxp3+CD4+T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 2006. 33: 386-390.
20. Ormandy, L. A., Hillemann, T., Wedemeyer, H., Manns, M. P., Greten, T. F. and Korangy, F., Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005. 65: 2457-2464.
21. Viguier, M., Lemaitre, F., Verola, O., Cho, M. S., Gorochov, G., Dubertret, L., Bachelez, H. et al., Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 2004. 173: 1444-1453.
22. Raiter, A., Rodionov, G., Novogrodsky, A. and Hardy, B., CD4+T lymphocytes as a primary cellular target for BAT mAb stimulation. Int. Immunol. 2000. 12: 1623-1628.
23. Shevach, E. M., Suppressor T cells: Rebirth, function and homeostasis. Curr. Biol. 2000. 10: R572-R575.
24. Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J. et al., Immunologic self-tolerance maintained by CD25+CD4+naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 1998. 10: 1969-1980.
25. Itoh, M., Takahashi, T., Sakaguchi, N., Kuniyasu, Y., Shimizu, J., Otsuka, F. and Sakaguchi, S., Thymus and autoimmunity: production of CD25+CD4+naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 1999. 162: 5317-5326.
26. Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W. et al., Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 2000. 192: 303-310.
27. Lutsiak, M. E., Semnani, R. T., De Pascalis, R., Kashmiri, S. V., Schlom, J. and Sabzevari, H., Inhibition of CD4(+)25+T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005. 105: 2862-2868.
28. Sharabi, A., Laronne-Bar-On, A., Meshorer, A. and Haran-Ghera, N., Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model. Cancer Prev. Res. (Phila) 2010. 3: 1265-1276.
29. Brode, S. and Cooke, A., Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit. Rev. Immunol. 2008. 28: 109-126.
30. Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B. et al., CD4+CD25+regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004. 34: 336-344.
31. Awwad, M. and North, R. J., Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 1988. 65: 87-92.
32. Ikezawa, Y., Nakazawa, M., Tamura, C., Takahashi, K., Minami, M. and Ikezawa, Z., Cyclophosphamide decreases the number, percentage and the function of CD25+CD4+regulatory T cells, which suppress induction of contact hypersensitivity. J. Dermatol. Sci. 2005. 39: 105-112.
33. North, R. J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982. 155: 1063-1074.
34. Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M. et al., Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008. 14: 3044-3051.
35. Curran, M. A., Montalvo, W., Yagita, H. and Allison, J. P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 2010. 107: 4275-4280.
36. Shen, Z., Zhou, S., Wang, Y., Li, R. L., Zhong, C., Liang, C. and Sun, Y., Higher intratumoral infiltrated Foxp3+Treg numbers and Foxp3+/CD8+ratio are associated with adverse prognosis in resectable gastric cancer. J. Cancer Res. Clin. Oncol. 2010. 136: 1585-1595.
37. Biller, B. J., Guth, A., Burton, J. H. and Dow, S. W., Decreased ratio of CD8+T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J. Vet. Intern. Med. 2010. 24: 1118-1123.
38. Watanabe, Y., Katou, F., Ohtani, H., Nakayama, T., Yoshie, O. and Hashimoto, K., Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010. 109: 744-752.
39. Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S. et al., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006. 66: 3381-3385.
40. Sutmuller, R. P., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N., Wildenberg, M. E., Allison, J. P., Toes, R. E. et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001. 194: 823-832.
41. Sakaguchi, S., Naturally arising CD4+regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004. 22: 531-562.
42. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999. 59: 3128-3133.
43. Ding, Z. C., Blazar, B. R., Mellor, A. L., Munn, D. H. and Zhou, G., Chemotherapy rescues tumor-driven aberrant CD4+T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 2010. 115: 2397-2406.
44. del Rio, M. L., Penuelas-Rivas, G., Dominguez-Perles, R., Ramirez, P., Parrilla, P. and Rodriguez-Barbosa, J. I., Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation. Eur. J. Immunol. 2005. 35: 3545-3560.
45. Ahlers, J. D., Belyakov, I. M., Terabe, M., Koka, R., Donaldson, D. D., Thomas, E. K. and Berzofsky, J. A., A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc. Natl. Acad. Sci. USA 2002. 99: 13020-13025.
46. Ghochikyan, A., Mkrtichyan, M., Loukinov, D., Mamikonyan, G., Pack, S. D., Movsesyan, N., Ichim, T. E. et al., Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J. Immunol. 2007. 178: 566-573.